Comparative Pharmacology
Head-to-head clinical analysis: CEFPROZIL versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPROZIL versus DURICEF.
CEFPROZIL vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefprozil, a second-generation cephalosporin, exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis, leading to cell lysis.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 12 hours for 10 days; for pharyngitis/tonsillitis: 500 mg orally every 24 hours for 10 days.
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
1.2-1.4 hours in adults with normal renal function; prolonged to 5-6 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateCefprozil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefprozil."
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Renal (primarily), approximately 60-70% unchanged in urine; biliary/fecal excretion accounts for <10%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic